Comparative Pharmacology
Head-to-head clinical analysis: ALYFTREK versus DEXAMETHASONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALYFTREK versus DEXAMETHASONE.
ALYFTREK vs DEXAMETHASONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALYFTREK (vutrisiran) is a transthyretin-directed small interfering RNA that binds to the 3' untranslated region of mutant and wild-type TTR mRNA, leading to its degradation via RNA interference, thereby reducing hepatic production of TTR protein and decreasing amyloid deposition.
Agonist at glucocorticoid receptors, leading to altered gene expression and suppression of inflammatory mediators.
For patients with cystic fibrosis (CF) who are heterozygous for the F508del mutation in the CFTR gene and a minimal function mutation (F/MF genotypes): elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 125 mg orally, two tablets in the morning, and ivacaftor 150 mg orally, one tablet in the evening, approximately 12 hours apart. For patients homozygous for F508del (F/F genotypes): elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 125 mg orally, two tablets in the morning, and ivacaftor 150 mg orally, one tablet in the evening.
0.5-24 mg/day oral, IV, IM in 2-4 divided doses; anti-inflammatory: 0.75-9 mg/day; multiple myeloma: 40 mg oral/IV once daily on days 1-4, 9-12, 17-20 every 28 days.
None Documented
None Documented
Clinical Note
moderateDexamethasone + Digoxin
"Dexamethasone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDexamethasone + Digitoxin
"Dexamethasone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDexamethasone + Deslanoside
"Dexamethasone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDexamethasone + Acetyldigitoxin
"Dexamethasone may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 72 hours after single dose and extends to ~120 hours at steady state due to dose-dependent elimination; allows once-weekly dosing.
Terminal elimination half-life 3-4 hours; clinically, duration of HPA suppression may exceed 24 hours due to prolonged receptor binding.
Primarily hepatic metabolism, with ~70% excreted in feces as metabolites and ~20% in urine (mostly as metabolites). <1% excreted unchanged in urine.
Primarily renal (65-80% as unchanged drug); minor biliary/fecal (<10%).
Category C
Category D/X
Corticosteroid/Beta2-Agonist Combination
Corticosteroid